MENU
+Compare
CRDF
Stock ticker: NASDAQ
AS OF
Aug 11, 12:10 PM (EDT)
Price
$2.35
Change
-$0.03 (-1.26%)
Capitalization
159M

CRDF Cardiff Oncology Forecast, Technical & Fundamental Analysis

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need... Show more

CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CRDF with price predictions
Aug 08, 2025

CRDF sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for CRDF moved above the 200-day moving average on July 18, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRDF advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .

CRDF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 178 cases where CRDF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 24, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CRDF as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CRDF turned negative on July 24, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

CRDF moved below its 50-day moving average on July 29, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CRDF crossed bearishly below the 50-day moving average on August 01, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.713) is normal, around the industry mean (18.662). P/E Ratio (0.000) is within average values for comparable stocks, (54.033). CRDF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.909). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (256.410) is also within normal values, averaging (286.048).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CRDF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CRDF is expected to report earnings to fall 2.95% to -20 cents per share on October 30

Cardiff Oncology CRDF Stock Earnings Reports
Q3'25
Est.
$-0.20
Q2'25
Missed
by $0.02
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.03
Q3'24
Beat
by $0.02
The last earnings report on July 29 showed earnings per share of -20 cents, missing the estimate of -18 cents. With 241.38K shares outstanding, the current market capitalization sits at 159.00M.
A.I. Advisor
published General Information

General Information

a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
11055 Flintkote Avenue
Phone
+1 858 952-7570
Employees
32
Web
https://www.cardiffoncology.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CBSTF0.10N/A
+4.41%
THE CANNABIST COMPANY HOLDINGS INC.
AXVEF0.22N/A
N/A
CDN MAVERICK CAP CORP.
RZSMF1.20N/A
N/A
Rizzoli Corriere della Sera Mediagroup SPA AZ
SEBYY9.80N/A
N/A
SEB S.A.
ASMXF483.96-0.04
-0.01%
ASM International N.V.

CRDF and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with NAMS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then NAMS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
-0.83%
NAMS - CRDF
42%
Loosely correlated
+10.24%
QURE - CRDF
41%
Loosely correlated
-1.26%
MRVI - CRDF
40%
Loosely correlated
+8.64%
AKBLF - CRDF
37%
Loosely correlated
N/A
ABSI - CRDF
37%
Loosely correlated
-2.41%
More